Clinical Utility of F-18-FDG PET/CT Concurrent with I-131 Therapy in Intermediate-to-High-Risk Patients with Differentiated Thyroid Cancer: Dual-Center Experience with 286 Patients
- Authors
- Lee, Jeong Won; Lee, Sang Mi; Lee, Dae Ho; Kim, Yeo Joo
- Issue Date
- Aug-2013
- Publisher
- Kexue Chubaneshe/Science Press
- Keywords
- differentiated thyroid cancer; F-18-fluorodeoxyglucose; positron emission tomography; radioiodine therapy
- Citation
- Journal of Nuclear Medicine, v.54, no.8, pp 1230 - 1236
- Pages
- 7
- Journal Title
- Journal of Nuclear Medicine
- Volume
- 54
- Number
- 8
- Start Page
- 1230
- End Page
- 1236
- URI
- https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/13489
- DOI
- 10.2967/jnumed.112.117119
- ISSN
- 0161-5505
1535-5667
- Abstract
- Patients with differentiated thyroid carcinoma (DTC) are treated with I-131 therapy after total thyroidectomy or surgical resection of recurrent tumor. However, some recurrent DTC lesions are not iodine-avid, which affects further treatment planning. The aim of this study was to evaluate the clinical benefit of F-18-FDG PET/CT performed concurrently with I-131 therapy in DTC patients with intermediate to high risk. Methods: We retrospectively enrolled 286 DTC patients at 2 Korean medical centers who comprised 2 different patient groups: 28 patients who underwent adjuvant I-131 treatment after curative surgical resection of recurrent tumor and 258 patients with intermediate to high risk who underwent I-131 ablation after total thyroidectomy. I-131 therapy and F-18-FDG PET/CT scanning were performed on the same day. Administration of L-thyroxine was withheld from all enrollees for 4 wk before I-131 treatment. Results: In 39 patients (14%), F-18-FDG PET/CT detected additional recurrent or metastatic lesions that were not detected on the posttherapy I-131 scan, and the treatment plan was changed for 30 patients (10%) based on such findings. Among the 28 patients receiving I-131 treatment after resection of recurrent tumor, PET/CT detected additional lesions in 46%, and treatment was changed in 43%. Assessing a subgroup of stage T3-T4N1 patients with tumor size > 2.0 cm, among 258 patients undergoing I-131 ablation after total thyroidectomy, we found that 25% had additional positive PET/CT results, and treatment changed for 17%. In contrast, 8% of stage T3-T4N1 patients with tumor size <= 2.0 cm, 6% of stage T1-T2N1 patients, and 3% of stage T3-T4N0 patients had additional positive PET/CT findings. Conclusion: F-18-FDG PET/CT performed concurrently with I-131 therapy detected additional lesions in 14% of DTC patients and was particularly helpful for detecting additional lesions in patients undergoing I-131 therapy after resection of recurrent tumor or in stage T3-T4N1 patients with tumor size > 2.0 cm.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Internal Medicine > 1. Journal Articles
- College of Medicine > Department of Radiology > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/13489)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.